purpos
articl
review
uniqu
challeng
offer
develop
treatment
acut
oppos
chronic
viral
diseas
extent
outstand
success
treatment
chronic
viru
infect
includ
human
immunodefici
viru
hiv
hepat
c
viru
hcv
detail
previou
articl
serv
encourag
invest
research
develop
aim
treatment
acut
viral
infect
acut
viral
infect
offer
uniqu
set
epidemiolog
technic
characterist
contribut
overal
possibl
discoveri
use
therapeut
agent
would
imposs
space
avail
examin
acut
viru
infect
chosen
compar
contrast
appar
similar
respiratori
viru
infect
caus
orthomyxovirus
influenza
flu
rhinovirus
adenovirus
paramyxovirus
includ
respiratori
syncyti
viru
rsv
consid
challeng
drug
discoveri
viru
famili
overcom
review
detail
discoveri
effort
aim
rsv
gener
exampl
acut
viral
infect
viru
illumin
challeng
promis
work
field
rsv
also
acut
viru
infect
current
interest
industri
post
emerg
multipl
potent
therapeut
combin
treat
hcv
final
review
interest
challeng
emerg
viral
infect
global
warm
subsequ
migrat
viral
vector
popular
global
travel
combin
spread
littl
known
virus
around
world
threaten
human
popul
graph
later
fig
show
overlay
epidem
four
common
respiratori
viru
famili
unit
kingdom
period
rsv
epidem
black
line
consist
featur
everi
winter
paramyxovirus
assum
less
import
rhinovirus
serotyp
present
much
year
influenza
viru
epidem
much
less
predict
timelin
clear
fear
global
pandem
influenza
much
overdu
adenovirus
becom
import
group
seroneg
individu
congreg
eg
armi
recruit
colleg
student
viru
attack
immunocompromis
differ
seen
epidemiolog
four
viru
famili
show
one
gener
respiratori
viru
theme
viru
need
consid
multipl
aspect
embark
drug
discoveri
project
key
issu
consid
initi
discoveri
project
follow
l
preval
signific
diseas
burden
caus
viru
l
diagnosi
specimen
access
speed
accuraci
test
l
altern
therapeut
approach
vaccin
immunotherapi
etc
l
therapeut
window
abil
interven
time
fashion
significantli
improv
outcom
patient
l
competit
rel
progress
discoveri
project
opportunitythreat
offer
common
issu
therapeut
area
drug
industri
mani
year
choic
target
protein
suitabl
diseas
virolog
field
becom
much
less
complex
viru
multipl
target
avail
well
understood
often
limit
step
start
antivir
discoveri
project
make
commerci
case
return
invest
suffici
justifi
work
issu
particularli
case
acut
viral
infect
histori
project
often
fail
get
ground
commerci
case
base
attempt
treat
otherwis
healthi
popul
approach
often
superfici
attract
simpli
number
patient
larg
real
medic
need
commerci
opportun
lie
find
patient
group
acut
infect
catastroph
patient
may
young
elderli
immunocompromis
tabl
list
four
viru
famili
chosen
illustr
issu
discoveri
agent
combat
acut
viru
infect
discuss
turn
follow
issu
around
emerg
viru
infect
rhinovirus
known
caus
common
colddon
mildest
infect
known
medicin
adult
see
two
five
infect
year
although
may
caus
irrit
morbid
gener
well
toler
attempt
treat
common
cold
agent
like
interferon
capsid
binder
gener
target
otherwis
healthi
popul
approach
led
failur
limit
benefit
compens
side
effect
observ
also
led
widespread
reluct
industri
invest
antivir
discoveri
program
common
cold
sever
outcom
rhinoviru
infect
wide
appreci
asthmat
chronic
obstruct
pulmonari
diseas
copd
patient
cystic
fibrosi
problem
develop
vaccin
passiv
immunotherapi
patient
infect
viru
may
one
serotyp
mandat
effort
develop
panrhinoviru
inhibitor
rhinovirus
member
picornaviru
famili
small
singlestrand
rna
virus
lesson
learn
discoveri
effort
group
provid
use
start
point
research
newli
discov
appreci
small
rna
virus
caus
signific
diseas
burden
includ
coronavirus
sarscov
merscov
enterovirus
share
similar
target
protein
broadspectrum
inhibitor
virus
would
attract
use
lifethreaten
diseas
caus
earli
discoveri
effort
sever
compani
identifi
differ
type
hydrophob
small
molecul
inhibit
rhinoviru
replic
compound
shown
bind
viru
particl
interfer
earli
stage
viral
replic
classic
experi
rossmann
group
determin
threedimension
structur
exampl
inhibitor
bound
viru
particl
show
bound
canyon
extern
structur
viral
capsid
protein
number
structur
studi
subsequ
confirm
bind
mode
recent
develop
compound
polioviru
enteroviru
well
rhinoviru
rhinoviru
consist
bind
mode
observ
inhibitor
rang
interact
key
residu
postul
notabl
hbond
p
interact
residu
mutat
observ
natur
deriv
serotyp
alongsid
mutat
observ
across
multipl
serotyp
chang
overcom
antivir
effect
inhibitor
reduc
bind
affin
drug
modif
proxim
bind
site
case
recent
describ
distanc
residu
bind
posit
compound
suggest
differ
effect
hypothesi
propos
mutat
stabil
collaps
conform
portion
protein
imped
inhibitor
access
ration
structur
argument
appear
major
featur
drug
develop
structur
type
modif
featur
effect
bind
affin
pharmacokinet
profil
structur
inhibitor
long
multipl
freeli
rotat
bond
fig
addit
metabol
labil
group
exampl
ester
oxim
common
pirodavir
fig
pleconaril
first
molecul
issu
address
incorpor
trifluoromethylsubstitut
oxadiazol
system
demonstr
satisfactori
oral
pharmacokinet
latest
inhibitor
vapendavir
util
benzisoxazol
replac
labil
function
isoster
appear
provid
oral
bioavail
compound
although
bioavail
rat
report
rather
larg
dose
mg
kg
retain
potenti
satur
metabol
process
may
occur
lower
dose
closer
therapeut
rang
recent
describ
inhibitor
type
certainli
demonstr
differ
perspect
site
bind
mode
capsid
inhibitor
due
compound
decreas
size
inhibitor
occupi
fraction
convent
bind
pocket
provid
interest
new
templat
medicin
optim
tabl
respiratori
virus
target
drug
discoveri
janssen
group
develop
seri
capsid
binder
show
potent
activ
select
strain
rhinoviru
seri
develop
appreci
emerg
variat
sensit
variou
rhinoviru
serotyp
need
compound
wider
spectrum
activ
work
culmin
pirodavir
enter
clinic
trial
challeng
studi
capsid
binder
physicochem
properti
compound
made
formul
difficult
intranas
spray
develop
compound
test
prophylaxi
treatment
mode
clear
antivir
effect
compound
use
six
time
day
prophylact
mode
treatment
data
effect
symptom
cold
disappoint
pleconaril
origin
research
winthrop
later
acquir
sanofi
pleconaril
licens
viropharma
use
clinic
trial
data
obtain
oral
formul
drug
viropharma
attempt
obtain
new
drug
applic
nda
trial
show
clear
effect
outcom
common
cold
benefit
day
resolut
clinic
symptom
unfortun
side
effect
although
moder
larg
girel
consid
sever
fda
limit
benefit
drug
also
induc
metabol
contracept
two
women
trial
becam
pregnant
outcom
clearli
demonstr
uphil
task
develop
medicin
consid
trivial
infect
detail
analysi
clinic
trial
laboratori
data
pleconaril
highlight
interest
challeng
type
rhinoviru
inhibitor
wide
variat
sensit
variou
serotyp
rhinoviru
drug
insensit
inhibit
resist
viru
variant
readili
isol
therapi
although
rel
fit
assess
recent
paper
extend
interest
capsid
binder
picornavirus
kelli
et
al
clearli
demonstr
fit
cost
resist
mutat
viru
scheringplough
inlicens
pleconaril
viropharma
began
develop
intranas
formul
prevent
rhinovirusinduc
exacerb
asthma
recent
updat
result
http
clinicaltrialsgov
websit
show
although
patient
enter
trial
came
contact
famili
member
proven
rhinoviru
infect
recruit
found
infect
vapendavir
aviragen
therapeut
previous
known
biota
pharmaceut
describ
earlier
current
phase
ii
trial
asthmat
vapendavir
display
broader
spectrum
activ
viru
isol
pleconaril
phase
ii
studi
seek
monitor
moderatetosever
asthmat
rhinoviru
season
start
dose
drug
placebo
proven
infect
outcom
includ
measur
asthma
exacerb
anticip
late
http
wwwaviragentherapeuticscom
variou
group
explor
possibl
challeng
studi
asthmat
provid
control
henc
clearcut
result
rega
group
continu
explor
possibl
advanc
capsid
binder
work
area
also
explor
possibl
extend
activ
member
picornaviru
famili
mello
et
al
show
rhinoviru
isol
group
c
replic
tradit
monolay
cell
cultur
may
inhibit
capsid
binder
inform
need
taken
account
design
new
agent
picornavirus
encod
proteas
encod
gene
proteas
essenti
replic
respons
cleavag
viral
polyprotein
activ
enzym
structur
compon
viral
encod
proteas
extens
explor
target
chronic
viral
infect
effort
inspir
pioneer
work
equival
rhinoviru
enzym
agouron
group
later
acquir
pfizer
team
use
structurebas
approach
optim
proteas
inhibitor
culmin
ruprintivir
formerli
potent
agent
activ
rhinoviru
isol
test
picornavirus
compound
peptidomimet
whose
design
base
upon
picornavir
cleavagesit
recognit
characterist
proteas
cleavag
occur
glutamin
glycin
residu
addit
rhinoviru
proteas
catalyt
triad
cystein
histidin
glutam
acid
geometri
similar
observ
trypsinlik
serin
proteas
suggest
incorpor
coval
modifi
warhead
specif
bunsatur
ester
present
incorpor
cyclic
butyramid
provid
optim
structur
shown
fig
detail
descript
optim
structur
element
publish
poor
aqueou
solubl
ruprintivir
render
formul
challeng
adopt
nasal
spray
formul
enabl
clinic
challeng
studi
explor
effect
drug
experiment
acquir
infect
signific
effect
viral
paramet
seen
especi
five
time
day
prophylact
dose
littl
effect
develop
rhinoviru
cold
high
concentr
drug
reach
nasal
epithelium
rais
question
concern
bioavail
drug
upper
respiratori
tract
urt
one
hand
relev
experiment
challeng
model
picornavirus
encod
rna
polymeras
gene
product
principl
appear
ideal
target
broadspectrum
inhibitor
share
somewhat
invari
rna
sequenc
review
ref
enorm
amount
academ
work
explor
structur
rna
polymeras
mani
picornavirus
mani
state
review
see
ref
varieti
picornaviru
polymeras
inhibitor
discov
though
screen
program
test
nucleosid
librari
encompass
purin
pyrimidin
nucleosid
well
potenti
nonnucleosid
inhibitor
clinic
impact
inhibitor
polymeras
chronic
viral
infect
suggest
optim
version
lead
might
high
util
given
extrem
plastic
picornaviru
genom
due
errorpron
rna
polymeras
combin
therapi
undoubtedli
import
develop
effect
broadspectrum
treatment
may
includ
improv
smallmolecul
inhibitor
type
discuss
earlier
also
biolog
agent
like
interferon
solubl
viral
receptor
consider
success
develop
vaccin
antivir
drug
treat
influenza
infect
unmet
medic
need
still
high
larg
due
plastic
viral
genom
mandat
manufactur
new
vaccin
viru
season
allow
rapid
develop
resist
viru
impetu
develop
new
approach
influenza
come
larg
potenti
emerg
new
pandem
viru
popul
littl
resist
respiratori
virus
influenza
alreadi
signific
problem
elderli
immunocompromis
asthmat
popul
accord
influenza
occur
global
annual
attack
rate
estim
adult
children
worldwid
annual
epidem
estim
result
million
case
sever
ill
death
earli
discoveri
effort
use
phenotyp
cellular
screen
antiinfluenza
activ
amantadin
discov
potent
inhibitori
effect
time
discoveri
littl
known
viru
gene
protein
encod
clinic
drug
shown
modest
efficaci
analog
amantadin
synthes
found
slightli
improv
profil
wide
studi
rimantidin
extens
use
former
soviet
union
review
zlydnikov
et
al
resist
mutant
easili
isol
map
viral
protein
know
protein
ion
channel
encod
within
viral
genom
discoveri
activ
neuraminidas
na
inhibitor
develop
widespread
resist
amantadin
rimantadin
clinic
interest
target
reduc
molecular
studi
resist
mutant
identifi
mechan
resist
within
structur
protein
area
deserv
attent
interest
combin
therapi
viru
famili
grow
recent
work
report
novel
scaffold
work
target
novel
adamantin
analog
fusion
activ
influenza
hemagglutinin
shown
essenti
releas
viral
particl
endosom
allow
replic
begin
arbidol
fig
small
indol
deriv
discov
develop
russia
approv
use
china
act
least
part
mechan
clinic
trial
data
report
russian
chines
studi
dissimilar
obtain
na
inhibitor
one
clinic
studi
report
http
clinicaltrialsgov
unfortun
compound
clearli
suboptim
rel
poor
activ
offtarget
effect
attempt
improv
arbidol
select
activ
use
indol
scaffold
yet
candid
compound
emerg
target
remain
exploit
probabl
new
lead
discoveri
exercis
far
wide
use
antivir
influenza
na
inhibitor
na
enzym
encod
viral
genom
present
extern
surfac
viru
particl
na
role
entri
exit
viru
host
cell
passag
viru
mucusrich
surfac
inhibitor
enzym
natur
substrat
analog
base
around
structur
fig
arbidol
zanamivir
oseltamivir
peramivir
laninamivir
octano
viral
receptor
sialic
acid
approv
na
inhibitor
zanamivir
fig
relenza
oseltamivir
fig
tamiflu
potent
inhibitor
enzym
viru
replic
tissu
cultur
zanamivir
poor
physicochem
characterist
formul
intranas
dose
oseltamivir
oral
prodrug
seen
widespread
use
drug
show
clear
effect
wellcontrol
experiment
challeng
model
influenza
infect
volunt
far
difficult
prove
compound
signific
effect
natur
acquir
influenza
infect
inde
controversi
still
activ
drug
clearli
effect
viral
load
effect
urt
symptom
seem
relat
viru
infect
seen
patient
without
proven
infect
time
discoveri
develop
drug
attent
focus
treatment
season
influenza
anxieti
potenti
pandem
newli
emerg
influenza
strain
led
extens
stockpil
govern
agenc
agent
stockpil
activ
signific
effect
return
invest
develop
drug
illustr
well
commerci
environ
vari
differ
virus
caus
urt
infect
anoth
signific
factor
use
na
inhibitor
concern
develop
signific
level
resist
drug
enhanc
emerg
influenza
influenza
season
carri
mutat
oseltamivir
resist
spread
rapidli
togeth
mutat
oseltamivir
resist
viru
carri
compensatori
mutat
allow
replic
normal
viru
spread
around
world
even
absenc
select
pressur
drug
subsequ
season
seen
rise
oseltamivir
resist
rate
background
level
isol
level
resist
na
inhibitor
even
lower
clear
due
real
differ
eas
mutant
gener
much
lower
use
drug
effort
continu
develop
improv
na
inhibitor
enhanc
activ
physicochem
properti
abil
inhibit
viru
isol
resist
na
inhibitor
peramivir
fig
develop
biocryst
costli
na
inhibitor
given
infus
recommend
case
oral
iv
administr
difficult
laninamivir
octano
fig
longact
na
inhibitor
develop
biota
collabor
daiichi
sankyo
drug
approv
use
japan
remain
phase
ii
trial
rest
world
compound
given
inhal
rout
singl
administr
drug
level
maintain
period
virus
rna
polymeras
influenza
make
attract
target
new
drug
polymeras
inhibitor
influenza
viru
identifi
either
screen
program
nucleosid
chemistri
recent
targetdriven
approach
subunit
enzym
favipiravir
fig
polymeras
inhibitor
advanc
develop
influenza
infect
compound
discov
toyama
chemic
japan
lead
optim
screen
program
hit
compound
activ
cellular
enzym
triphosph
form
inhibit
viral
polymeras
activ
influenza
rang
mm
vitro
assay
favipiravir
shown
activ
two
japanes
phase
iii
trial
licens
japan
stockpil
pandem
influenza
current
drug
phase
iii
trial
unit
state
treat
influenza
adult
use
much
higher
dose
japanes
dose
g
load
dose
follow
mg
twice
day
us
dose
load
dose
g
plu
mg
four
time
day
favipiravir
weak
activ
wide
varieti
rna
virus
includ
ebola
viru
clinic
trial
data
await
efficaci
drug
latter
wide
varieti
pyrimidin
purin
nucleosid
claim
activ
influenza
virus
unfortun
date
none
found
suffici
select
viru
host
cell
enzym
develop
nonnucleosid
polymeras
inhibitor
develop
vertex
licens
johnson
johnson
renam
compound
discov
inhibitor
capsnatch
activ
subunit
viral
rna
polymeras
inde
occupi
gtp
capbind
site
preclin
studi
compound
show
excel
activ
influenza
anim
model
diseas
unfortun
compound
activ
influenza
b
strain
interest
activ
longer
window
activ
seen
na
inhibitor
stimul
invest
barda
phase
iii
program
compound
treatment
patient
hospit
influenza
infect
mani
influenza
program
discov
util
phenotyp
cellular
assay
initi
screen
limit
compound
identifi
sever
measur
antivir
activ
identif
kinas
inhibitor
templat
hit
perhap
reflect
focus
sourc
compound
also
exampl
success
reus
druglik
compound
type
provid
kinasebas
screen
set
specif
seri
pyrimidin
azaindol
emerg
screen
signific
activ
repres
compound
fig
project
support
crystallographi
sever
structur
gener
compound
bound
gtp
capbind
domain
reveal
key
hydrogenbond
interact
azaindol
lysin
glutam
acid
side
chain
bind
site
interact
delin
clinic
compound
carboxyl
acid
introduc
part
optim
process
result
fig
endonucleas
activ
pa
subunit
polymeras
target
merck
group
although
project
lead
clinic
candid
lead
becam
excel
start
point
success
program
led
hiv
integras
inhibitor
enzym
share
similar
activ
site
two
compani
pa
inhibitor
clinic
trial
shionogi
phase
japan
alio
j
j
challeng
studi
unit
state
http
clinicaltrialsgov
clear
clinic
need
interest
opportun
exist
antiinfluenza
research
truli
effect
approach
pandem
manag
combin
regimen
use
differ
inhibitor
class
would
appropri
context
concept
combin
polymeras
pa
inhibitor
provid
broadspectrum
therapeut
appeal
adenovirus
caus
varieti
import
human
anim
infect
yet
littl
progress
develop
antivir
drug
treat
diseas
given
size
adenoviru
genom
number
attract
target
encod
therein
stabil
doublestrand
dna
viral
genom
antivir
drug
could
clearli
develop
suffici
commerci
incent
exist
three
major
opportun
infecti
viral
conjunct
lung
infect
immunocompromis
especi
transplant
patient
epidem
adenoviru
pneumonia
young
adult
especi
militari
recruit
student
brought
close
proxim
due
enlist
start
colleg
conjunct
ocular
inflamm
caus
viru
bacterium
allergen
adenoviru
infect
account
viral
conjunct
rapid
diagnost
test
point
care
avail
would
aid
rapid
treatment
sign
interest
area
specialist
ophthalm
compani
difficult
get
accur
estim
number
patient
countri
infect
notifi
adenoviru
infect
immunocompromis
patient
major
threat
infect
especi
common
young
recipi
stem
cell
transplant
given
otherwis
excel
prognosi
patient
signific
number
complet
lack
treatment
option
indic
may
repres
orphan
drug
design
attract
price
support
develop
militari
support
enabl
develop
vaccin
adenoviru
type
use
extens
us
armi
complex
natur
adenoviru
famili
mitig
develop
panfamili
vaccin
cidofovir
nucleotid
analog
discov
pragu
holi
group
develop
gilead
treatment
cytomegaloviru
cmv
retin
aid
patient
major
problem
develop
effect
combin
regimen
first
nucleotid
analog
approv
human
use
compound
activ
rang
dna
virus
includ
adenoviru
use
limit
nephrotox
lack
oral
avail
chimerix
use
proprietari
lipid
conjug
technolog
produc
oral
avail
prodrug
cidofovir
brincidofovir
primari
aim
reduc
impact
cmv
immunocompromis
brincidofovir
oral
avail
avoid
issu
cidofovir
therapi
develop
compound
becam
target
social
media
campaign
compassion
use
young
patient
adenoviru
infect
therapi
avail
data
ongo
open
label
phase
iii
trial
stem
cell
transplant
patient
adenoviru
infect
complet
enrol
aug
await
http
clinicaltrialsgov
unfortun
trial
appear
shown
therapeut
benefit
although
viral
load
reduc
http
wwwchimerixcom
may
nicox
develop
ncx
viral
conjunct
ncx
carragelos
iotacarrageenan
sulfat
galactos
polym
deriv
red
seawe
antivir
properti
carragelos
inhibit
virus
bind
enter
human
cell
reduc
viral
replic
associ
symptom
carragelos
alreadi
avail
without
prescript
treatment
respiratori
viral
infect
antivir
activ
demonstr
preclin
studi
includ
three
import
adenovirus
caus
conjunct
nicox
plan
conduct
clinic
investig
ncx
medic
devic
http
wwwnicoxcom
paramyxovirus
quit
distinct
orthomyxovirus
influenza
virus
complet
differ
genom
structur
epidemiolog
despit
group
caus
infect
respiratori
tract
rsv
clinic
import
member
paramyxovirida
famili
first
isol
two
major
serotyp
rsv
b
altern
caus
similar
diseas
rsv
highli
infecti
transmit
respiratori
secret
via
close
contact
infect
individu
droplet
contamin
surfac
healthi
adult
rsv
one
caus
winter
cold
infant
viru
caus
week
respiratori
tract
diseas
infant
continu
excret
viru
sever
week
age
virtual
children
infect
viru
infect
rsv
induc
partial
protect
subsequ
infect
occur
even
winter
season
rsv
signific
pathogen
young
immunocompromis
elderli
l
rsv
new
born
infant
unit
state
infant
year
hospit
last
year
million
outpati
consult
rsv
everi
year
infant
prime
candid
safe
effect
oral
therapi
mortal
rate
young
risk
infant
develop
countri
includ
unit
state
care
babi
rsv
infect
impos
major
burden
hospit
sector
limit
capac
undertak
routin
surgeri
l
rsv
immunocompromis
medic
compromis
patient
rsv
major
issu
immunocompromis
natur
caus
cancer
chemotherapi
deliber
transplant
although
numer
less
signific
consider
invest
patient
mandat
treatment
l
rsv
elderli
increas
awar
burden
caus
rsv
elderli
year
without
major
influenza
epidem
ie
year
see
fig
rsv
signific
caus
morbid
mortal
million
consult
physician
unit
state
year
due
rsv
infect
viru
also
signific
problem
adult
copd
major
caus
exacerb
care
home
rsv
caus
annual
epidem
winter
season
influenza
infect
otherwis
healthi
adult
develop
sever
cold
normal
recov
unaid
consequ
therapi
develop
treat
firstli
infant
children
diseas
sever
term
durat
sever
possibl
outcom
studi
shown
children
see
three
physician
prior
hospit
admiss
present
multipl
prescrib
opportun
secondli
compromis
adult
patient
treat
physician
would
gener
well
awar
need
survey
patient
rsv
infect
use
effect
remedi
quickli
effici
final
adult
popul
treatment
local
epidem
would
use
prevent
spread
lifethreaten
infect
concept
insuffici
time
therapeut
intervent
respiratori
viru
infect
deriv
influenza
field
regard
outmod
due
longer
durat
rsv
diseas
infant
adult
wide
accept
expert
field
smallmolecul
drug
could
effect
either
treatment
prophylaxi
two
agent
approv
treatment
rsv
infect
first
ribavirin
nucleosid
analog
discov
antirsv
activ
screen
program
clinic
use
restrict
due
limit
antivir
potenc
inher
toxic
teratogen
potenti
approv
agent
prophylact
monoclon
antibodi
synagi
paluvizimab
market
astrazeneca
antibodi
interact
f
glycoprotein
viru
see
succeed
text
shown
provid
protect
infant
gain
widespread
use
protect
prematur
babi
cost
therapi
per
infant
winter
season
limit
wider
uptak
thu
obviou
clinic
need
new
smallmolecul
inhibitor
viru
rsv
encod
two
surfac
glycoprotein
f
g
protein
g
dispens
tissu
cultur
delet
attenu
viru
infect
f
protein
essenti
entri
viru
host
cell
express
protein
cell
membran
caus
celltocel
fusion
lead
giant
syncytia
characterist
rsv
infect
sinc
earli
discoveri
inhibitor
fusion
rsv
viru
particl
host
cell
could
readili
identifi
highthroughput
screen
great
deal
work
done
refin
potenc
select
varieti
structur
type
inhibitor
earli
work
field
survey
previou
review
contemporari
research
led
highresolut
threedimension
understand
fusion
process
inhibit
excel
detail
overview
f
protein
structur
function
see
battl
et
al
describ
structur
analysi
inhibitor
interact
prehairpin
structur
rsv
fusion
protein
work
number
inhibitor
structur
dock
trimer
model
fusion
complex
base
upon
crystal
structur
bound
prefus
construct
although
allencompass
ration
descript
bind
druglik
structur
divers
inhibitor
evid
studi
fig
provid
annot
version
bind
mode
substitut
analysi
structur
relat
evid
hydrophob
pp
natur
bind
biota
compound
presum
take
advantag
addit
energet
benefici
polar
interact
virtu
amin
incorpor
inhibitor
exhibit
potenc
laboratori
strain
rsv
oral
bioavail
discoveri
progress
toward
clinic
evalu
presatovir
describ
recent
moder
activ
screen
hit
fig
poor
oral
pharmacokinet
profil
transform
effici
manner
clinic
compound
note
role
pendant
amin
presatovir
perhap
incorpor
target
potenti
saltbridg
bind
interact
describ
earlier
recent
disclosur
draw
comparison
improv
lung
distribut
properti
presatovir
alcohol
analog
fig
advantag
basic
aminecontain
compound
ration
product
interact
lung
epitheli
cell
phospholipid
phosphatidyl
cholin
fatti
acid
pulmonari
surfact
date
less
inform
avail
regard
biota
compound
draffan
et
al
disclos
gener
structur
compound
potent
human
epitheli
airway
model
ec
nm
variabl
clinic
isol
data
ec
appear
around
nm
exhibit
oral
bioavail
quot
rat
dog
dose
mg
kg
efficaci
cotton
rat
model
describ
reduct
viral
titer
observ
mg
kg
patent
support
gener
structur
describ
exampl
fig
one
potent
exampl
nm
cytopath
effect
assay
failur
singl
fusion
inhibitor
reach
market
may
reflect
attrit
rate
typic
pharmaceut
develop
gener
leav
open
question
clinic
valid
context
first
success
clinic
studi
fusion
inhibitor
recent
report
gilead
compound
given
rapidli
reduc
viral
load
symptom
rsv
diseas
volunt
confirm
rsv
infect
compound
lead
group
fusion
program
j
j
biota
hold
teva
ark
therapeut
revir
tabl
give
overview
stage
develop
effort
clinic
studi
activ
debat
ultim
clinic
util
fusion
inhibitor
given
rel
rapid
emerg
resist
mutant
vitro
studi
first
observ
pioneer
work
bm
group
subsequ
yan
et
al
show
mutant
obtain
novel
fusion
inhibitor
structur
map
region
protein
fusion
inhibitor
mutant
group
claim
one
mutant
equal
pathogen
wildtyp
viru
murin
model
rsv
extens
use
made
differenti
human
airway
epithelium
model
rsv
replic
measur
fit
resist
mutant
mutant
becom
less
sensit
fusion
inhibitor
paid
cost
replic
effici
clinic
presatovir
hydroxyl
analog
data
show
although
resist
mutant
occur
human
treat
fusion
inhibitor
gilead
effect
reduc
viru
load
sign
symptom
diseas
replic
rna
rsv
requir
four
viral
proteinsdth
protein
requir
transcript
nucleocapsid
n
phosphoprotein
p
larg
l
protein
complex
provid
varieti
potenti
target
viral
inhibit
vitro
replicon
system
avail
measur
role
n
p
l
rna
duplic
role
three
protein
gradual
becom
clearer
start
see
fruit
research
emerg
develop
program
aim
target
recent
public
exampl
examin
druggabl
pocket
np
interfac
use
highresolut
structur
group
identifi
compound
base
dock
studi
use
structur
confirm
site
viabl
target
sever
compound
target
differ
aspect
rsv
replic
variou
stage
preclin
clinic
develop
see
tabl
alio
research
program
direct
toward
identif
nucleosid
could
inhibit
rsv
polymeras
chain
termin
larg
number
structur
divers
nucleosid
design
screen
cellbas
rsv
assay
nucleosid
analog
also
convert
triphosph
screen
inhibit
rsv
rnadepend
rna
polymeras
activ
one
compound
difluorocytidin
fig
exhibit
potent
inhibit
cytopath
effect
longstrain
rsv
ec
mm
furthermor
correspond
triphosph
identifi
potent
rsv
polymeras
inhibitor
ic
mm
intens
primarili
safetyguid
optim
process
furnish
select
inhibitor
rsv
isobutyryl
prodrug
inhibitor
term
fig
show
accept
oral
bioavail
hamster
rat
monkey
progress
clinic
trial
like
subject
recent
patent
file
pulmocid
ltd
appear
deriv
seri
rsv
inhibitor
exemplifi
origin
describ
yamanouchi
elabor
gilead
astrazeneca
highmolecularweight
lowsolubl
compound
astrazeneca
gilead
guis
character
weak
base
structur
modif
evolut
shown
fig
intend
inhal
dose
presum
increas
molecular
weight
clogp
context
addit
fluoro
toluidin
fragment
molecul
noteworthi
earlier
repres
chemotyp
howev
retain
poorli
lung
tissu
although
treatment
rsv
infect
like
short
term
longerterm
regimen
optim
elderli
prophylaxi
may
requir
combin
therapi
target
multipl
differ
viral
target
would
optim
antivir
effect
reduc
risk
signific
resist
emerg
tabl
smallmolecul
inhibitor
rsv
replic
develop
alio
part
j
j
nucleosid
analog
inhibit
rna
polymeras
activ
potent
activ
viral
challeng
studi
current
earli
phase
ii
trial
infant
pulmocid
nonnucleosid
rna
polymeras
inhibitor
physic
characterist
suitabl
inhal
administr
current
formal
preclin
studi
ribavirin
multipl
gener
licens
medicin
whose
limit
activ
rsv
still
matter
controversi
major
mechan
rsv
probabl
hypermut
via
rna
replic
complex
novarti
rsv
interact
n
protein
prove
effect
earli
clinic
studi
fig
initi
hit
nucleosid
discov
alio
optim
prodrug
isobutyryl
prodrug
function
shown
blue
key
optim
modif
highlight
red
impact
climat
chang
spread
insect
vector
grow
virus
emerg
welldocu
human
pathogen
whose
geograph
rang
limit
larg
increas
global
travel
busi
leisur
also
creat
opportun
viru
transport
around
world
hour
day
new
viru
emerg
clamor
aris
new
vaccin
drug
control
infect
hurri
clinic
trial
use
agent
limit
preclin
valid
result
rare
repurpos
effort
prove
use
genom
function
divers
across
viral
pathogen
mandat
specif
drug
optim
effort
despit
preced
broadspectrum
antibacteri
agent
altern
approach
identifi
antivir
agent
work
host
target
field
remain
infanc
present
brief
overview
recent
viral
epidem
illustr
point
end
altern
scenario
pandem
prepared
sarscov
appear
appear
spread
small
mammal
china
human
pass
human
human
via
close
contact
respiratori
secret
either
directli
fomit
viru
member
corona
viru
famili
member
known
caus
mild
symptom
like
common
cold
sar
epidem
spread
rapidli
air
travel
infect
patient
caus
infect
mortal
rate
http
wwwwhoint
epidem
control
strict
public
health
measuresdisol
patient
provid
highqual
support
viru
caus
new
case
sinc
coronavirus
small
rna
virus
encod
replicas
proteas
similar
rhinovirus
see
preced
text
target
attempt
made
util
knowledg
gain
latter
acceler
drug
develop
decad
later
strong
candid
molecul
emerg
coronaviru
replicas
complex
studi
extens
sinc
quit
differ
small
rna
virus
failur
go
promis
idea
candid
drug
probabl
result
lack
commerci
market
sar
drug
anoth
coronaviru
merscov
emerg
viru
thought
transfer
human
bat
bat
natur
reservoir
mani
coronavirus
camel
major
intermedi
host
merscov
spread
readili
human
human
nevertheless
viru
caus
small
epidem
mainli
saudi
arabia
total
case
relat
death
case
export
sever
countri
includ
south
korea
case
result
though
infect
healthcar
set
good
infect
control
measur
effect
arriv
second
coronaviru
signific
healthcar
impact
reawaken
interest
vaccin
drug
research
ebola
caus
filoviru
first
recogn
sudan
congo
recent
outbreak
began
largest
date
case
death
infect
mortal
rate
transport
via
air
travel
natur
host
ebola
viru
thought
fruit
bat
infect
human
occur
contact
dead
anim
tissu
bodi
fluid
humantohuman
transmiss
occur
similar
rout
ebola
viru
belong
filovirida
famili
mononegaviral
order
paramyxovirida
famili
given
clinic
preced
relat
virus
viral
rna
polymeras
logic
target
drug
discoveri
sever
group
screen
nucleosid
librari
identifi
lead
exist
nucleosid
antivir
favipiravir
see
section
influenza
virus
brincidofovir
see
section
adenoviru
biocryst
shown
activ
anim
model
unfortun
none
use
earli
enough
epidem
obtain
indic
clinic
efficaci
work
underway
look
select
ebola
viru
nucleosid
inhibitor
identifi
novel
inhibitor
west
african
ebola
strain
ebola
speci
cyano
group
fig
provid
potenc
select
viral
polymeras
clink
pyrrolo
base
fragment
fig
stabl
deglycosyl
program
identifi
suitabl
prodrug
provid
monophosphoramid
potent
vitro
activ
multipl
filovirus
ec
valu
mm
rang
ref
http
wwwusamriidarmymil
oct
rhesu
monkey
model
ebola
infect
compound
effect
therapeut
mode
activ
filovirus
also
arenavirus
coronavirus
compound
clinic
potenti
mandat
use
scottish
nurs
contract
ebola
infect
work
patient
sierra
leon
treat
royal
free
hospit
london
discharg
jan
readmit
hospit
oct
ebola
viru
infect
relaps
form
acut
mening
consequ
success
vivo
test
gilead
file
ind
juli
use
treat
ebola
viru
diseas
phase
test
healthi
human
volunt
began
august
scottish
nurs
hospit
earli
octob
suffici
data
obtain
support
compassion
use
drug
virus
belong
paramyxovirida
famili
order
mononegaviral
quit
close
relat
rsv
virus
natur
host
fruit
bat
hendra
viru
first
describ
caus
agent
equin
epidem
hendra
town
queensland
australia
fatal
rate
hors
human
infect
contact
diseas
hors
outbreak
hendra
occur
sinc
viru
emerg
vaccin
avail
hors
littl
data
efficaci
nipah
viru
emerg
pig
farm
malaysia
human
infect
death
viru
may
abil
transfer
human
caus
respiratori
infect
viru
natur
host
thought
fruit
bat
fruit
bat
excret
viru
urin
probabl
contamin
pig
feed
sinc
eight
outbreak
occur
bangladesh
neighbor
area
india
emerg
virus
probabl
relat
loss
chang
habitat
due
human
encroach
virus
would
appear
potenti
widespread
dissemin
discoveri
work
justifi
ribavirin
use
experiment
anim
model
patient
equivoc
result
discoveri
effort
describ
earlier
relat
rsv
provid
rational
explor
fusion
inhibitor
nucleosid
although
zika
viru
discov
survey
arthropodborn
virus
uganda
receiv
littl
attent
recent
outbreak
south
america
viru
move
across
pacif
arriv
south
america
brazil
thought
million
case
infect
brazil
viru
appear
spread
much
rapidli
america
seen
africa
give
littl
opportun
develop
countermeasur
zika
member
flaviviru
genera
flavivirida
famili
member
includ
yellow
fever
viru
yfv
west
nile
viru
dengu
viru
good
reason
think
effect
vaccin
antivir
medic
develop
infect
recent
outbreak
manifest
guillainbarr
syndrom
fetal
abnorm
associ
zika
infect
unclear
whether
result
larger
patient
popul
whether
viru
evolv
cn
tropism
spread
rapid
spread
zika
probabl
due
increas
human
travel
northerli
spread
viral
vector
aed
aegypti
aed
albopictu
fig
phosphoramid
prodrug
parent
nucleosid
success
antivir
discoveri
program
relat
flaviviru
hepat
c
provid
solid
platform
discoveri
antizika
compound
recent
resurg
yfv
angola
alreadi
spread
china
kenya
congo
reawaken
awar
infect
yfv
flaviviru
name
deriv
yellow
fever
caus
case
per
year
death
despit
avail
effect
afford
vaccin
current
shortag
vaccin
stock
precipit
live
debat
increas
number
peopl
protect
dilut
vaccin
untest
measur
outbreak
illustr
danger
complac
infecti
diseas
antivir
treatment
yfv
would
use
rapidrespons
context
previou
section
illustr
grow
threat
virus
emerg
reemerg
reservoir
chang
environ
new
emerg
stimul
fresh
research
effort
frequent
lack
sustain
commit
invest
provid
clinic
effect
agent
episod
threat
abat
greater
coordin
intern
agenc
might
provid
discoveri
program
rel
nomin
cost
produc
credibl
lead
molecul
identifi
virus
threaten
us
small
invest
could
save
thousand
live
futur
emerg
viral
epidem
aim
articl
survey
progress
discoveri
new
antivir
drug
treat
acut
viral
infect
antivir
therapeut
area
one
great
success
stori
pharmaceut
industri
case
hiv
infect
seen
introduct
new
drug
use
ever
sophist
combin
formul
extend
life
span
infect
individu
near
normal
good
qualiti
life
hepat
c
seen
effect
cure
patient
reduc
treatment
time
year
week
success
appli
acut
viral
infect
use
four
exampl
respiratori
tract
infect
sought
illustr
differ
challeng
need
overcom
bring
new
medicin
patient
although
scientif
challeng
far
trivial
greater
problem
make
invest
case
support
discoveri
effort
see
also
directact
antivir
agent
treatment
hepat
c
viru
infect
